Opaleye Management Inc. Fulcrum Therapeutics, Inc. Transaction History

Opaleye Management Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.98 - $9.31 $926,900 - $1.44 Million	155,000 Added 119.23%	285,000 $1.77 Million
Q4 2023 Feb 14, 2024	BUY	$3.18 - $6.86 $413,400 - $891,800	130,000 New	130,000 $877,000
Q2 2023 Aug 14, 2023	BUY	$2.26 - $3.8 $324,535 - $545,680	143,600 New	143,600 $473,000
Q2 2022 Aug 15, 2022	SELL	$4.2 - $24.0 $571,200 - $3.26 Million	-136,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$9.96 - $23.65 $1.35 Million - $3.22 Million	136,000 New	136,000 $3.22 Million
Q1 2021 May 18, 2021	SELL	$10.94 - $15.32 $966,002 - $1.35 Million	-88,300 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$7.84 - $13.4 $2.85 Million - $4.87 Million	-363,700 Reduced 80.46%	88,300 $1.03 Million
Q3 2020 Nov 16, 2020	BUY	$7.22 - $20.7 $3.26 Million - $9.36 Million	452,000 New	452,000 $3.58 Million

150

52.2M

6.91M

1.9M

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $156M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.